Immunovaccine, Inc. (immunovaccine)

Oncology Corporate Profile

HQ Location

1344 Summer Street, Suite 412
Halifax, Nova Scotia, Canada B3H 0A8

Company Description

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company's DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvants to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase I human clinical trials. Lead cancer vaccine therapy, DPX-Survivac, is expected to enter Phase II clinical studies in 2014, in ovarian cancer and glioblastoma (brain cancer). The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV) and anthrax.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
DPX-0907immunotherapyDiffuse large B-cell Lymphoma (DLBCL)II
DPX-0907immunotherapyBreast cancerI
DPX-0907immunotherapyOvarian cancerI
DPX-Survivac (+ epacadostat and cyclophosphamide)immunotherapyOvarian cancerI
DPX-0907immunotherapyProstate cancerI

View additional information on product candidates here »


Recent News Headlines

There are no news items to display